$13.77
0[0.00%]
At close: Apr 18
$13.77
0[0.00%]
PreMarket: 4:00PM EDT
NeoGenomics
(NASDAQ:NEO)Latest News for NeoGenomics Stock (NASDAQ:NEO)
NeoGenomics Stock (NASDAQ: NEO)
Categories: All
Monday, March 18, 2024
Friday, March 15, 2024
Monday, February 26, 2024
Thursday, February 22, 2024
Wednesday, February 21, 2024
- Why International Flavors & Fragrances Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionAvi Kapoor - Feb 21, 2024, 1:50PM
- Why Is Cancer Genetics Test-Focused NeoGenomics Stock Trading Higher Today?Vandana Singh - Feb 21, 2024, 11:01AM
- Toll Brothers Posts Upbeat Earnings, Joins Exelon, Garmin, Bausch + Lomb And Other Big Stocks Moving Higher On WednesdayAvi Kapoor - Feb 21, 2024, 10:47AM
- NeoGenomics shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY24 adjusted EPS guidance above estimates.Benzinga Newsdesk - Feb 21, 2024, 8:38AM
- Why NeoGenomics Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving PremarketAvi Kapoor - Feb 21, 2024, 8:06AM
- 12 Health Care Stocks Moving In Wednesday's Pre-Market SessionBenzinga Insights - Feb 21, 2024, 8:06AM
- Evaluating NeoGenomics: Insights From 4 Financial AnalystsBenzinga Insights - Feb 21, 2024, 7:00AM
- Needham Maintains Buy on NeoGenomics, Raises Price Target to $24Benzinga Newsdesk - Feb 21, 2024, 5:32AM
Tuesday, February 20, 2024
- NeoGenomics shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY24 adjusted EPS guidance above estimates.Benzinga Newsdesk - Feb 20, 2024, 5:06PM
- 12 Health Care Stocks Moving In Tuesday's After-Market SessionBenzinga Insights - Feb 20, 2024, 4:31PM
- NeoGenomics Sees FY24 Adj. EPS $0.04 Vs $(0.08) Est.Benzinga Newsdesk - Feb 20, 2024, 4:27PM
- Recap: NeoGenomics Q4 EarningsBenzinga Insights - Feb 20, 2024, 4:10PM
- NeoGenomics Q4 2023 Adj EPS $0.03 Beats $(0.02) Estimate, Sales $155.55M Beat $152.54M EstimateBenzinga Newsdesk - Feb 20, 2024, 4:09PM
- Earnings Scheduled For February 20, 2024Benzinga Insights - Feb 20, 2024, 6:52AM
Monday, February 19, 2024
Thursday, February 01, 2024
Friday, December 29, 2023
- Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About YetChris Katje - Dec 29, 2023, 11:04AM
- Expedia To Rally Around 10%? Here Are 10 Top Analyst Forecasts For FridayAvi Kapoor - Dec 29, 2023, 9:20AM
- TD Cowen Maintains Outperform on NeoGenomics, Lowers Price Target to $19Benzinga Newsdesk - Dec 29, 2023, 8:40AM
- BTIG Maintains Buy on NeoGenomics, Lowers Price Target to $21Benzinga Newsdesk - Dec 29, 2023, 7:19AM
Thursday, December 28, 2023
- Why DouYu International Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionAvi Kapoor - Dec 28, 2023, 1:07PM
- US Court Prohibits NeoGenomics To Sell Type Of Diagnostic Kits To Detect Smaller Number Of Cancer Cells, Favoring Natera In LawsuitVandana Singh - Dec 28, 2023, 12:57PM
- 12 Health Care Stocks Moving In Thursday's Intraday SessionBenzinga Insights - Dec 28, 2023, 12:31PM
- NeoGenomics, Energy Fuels And Other Big Stocks Moving Lower On ThursdayAvi Kapoor - Dec 28, 2023, 10:53AM
- 7 Analysts Have This To Say About NeoGenomicsBenzinga Insights - Dec 28, 2023, 10:00AM
- Needham Reiterates Buy on NeoGenomics, Maintains $21 Price TargetBenzinga Newsdesk - Dec 28, 2023, 9:05AM
- NeoGenomics shares are trading lower after Natera won a preliminary injuction in a patent infringement lawsuit against NeoGenomics' RaDar test.Benzinga Newsdesk - Dec 28, 2023, 9:02AM
- NeoGenomics Announced That Subsidiary Neogenomics Laboratories Will Appeal The Preliminary Injunction Issued By The U.S. District Court For The Middle District Of North CarolinaBenzinga Newsdesk - Dec 28, 2023, 8:13AM
- Natera Wins Preliminary Injunction In Patent Infringement Lawsuit Against NeoGenomics' RaDaR TestBenzinga Newsdesk - Dec 28, 2023, 2:02AM
Tuesday, December 05, 2023
Wednesday, November 08, 2023
Tuesday, November 07, 2023
Monday, November 06, 2023
- NeoGenomics Q3 2023 Sales $151.95M Beat $142.00M EstimateBenzinga Newsdesk - Nov 6, 2023, 5:26PM
- NeoGenomics Sees FY23 Revenue $585M-$592M Vs $573.19M Est.Benzinga Newsdesk - Nov 6, 2023, 4:49PM
- NeoGenomics Q3 EPS $0 Beats $(0.07) Estimate, Sales $152.00M Beat $141.65 EstimateBenzinga Newsdesk - Nov 6, 2023, 4:47PM
- Earnings Scheduled For November 6, 2023Benzinga Insights - Nov 6, 2023, 8:24AM